Literature DB >> 34354245

JATENZO®: Challenges in the development of oral testosterone.

Mehul Patel1, Akhil Muthigi2, Ranjith Ramasamy3.   

Abstract

Testosterone therapy (TT) for the treatment of testosterone deficiency (TD) can be administered via several routes of administration. Due to a variety of concerns such as hepatotoxicity, an oral formulation has long been absent in the United States. Recently, JATENZO® (testosterone undecanoate) oral capsules was approved by the US FDA as an oral option for men suffering from TD. In this article, we will discuss the history and challenges in the development of a viable oral formulation of exogeneous TT and examine how JATENZO® addresses these concerns.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2021        PMID: 34354245     DOI: 10.1038/s41443-021-00461-4

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  6 in total

Review 1.  Hepatic neoplasms associated with contraceptive and anabolic steroids.

Authors:  K G Ishak
Journal:  Recent Results Cancer Res       Date:  1979

2.  Effects of various modes of androgen substitution therapy on erythropoiesis.

Authors:  F Jockenhövel; E Vogel; W Reinhardt; D Reinwein
Journal:  Eur J Med Res       Date:  1997-07-28       Impact factor: 2.175

3.  Effects of testosterone replacement in hypogonadal men.

Authors:  P J Snyder; H Peachey; J A Berlin; P Hannoush; G Haddad; A Dlewati; J Santanna; L Loh; D A Lenrow; J H Holmes; S C Kapoor; L E Atkinson; B L Strom
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

4.  Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

Authors:  L Katznelson; J S Finkelstein; D A Schoenfeld; D I Rosenthal; E J Anderson; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1996-12       Impact factor: 5.958

5.  A Cross-sectional Survey on the Preference of Patients with Rheumatoid Arthritis for Route of Administration of Disease-Modifying Anti-Rheumatic Drugs: Oral Target-Specific Versus Parenteral Biologic.

Authors:  Yonatan Edel; Iftach Sagy; Elisheva Pokroy-Shapira; Shirly Oren; Ariela Dortort Lazar; Mohammad Egbaria; Shachaf Shiber; Bat Sheva Tal; Yair Molad
Journal:  Isr Med Assoc J       Date:  2020-03       Impact factor: 0.892

6.  Liver damage from long-term methyltestosterone.

Authors:  D Westaby; S J Ogle; F J Paradinas; J B Randell; I M Murray-Lyon
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.